Home

Patrick Lamy

CIK 1961273 · See Remarks · last filed 2025-12-09

Patrick Lamy is a corporate insider who has filed 22 SEC Form 4 insider transactions across 1 company since 2023. The most recent filing, for AKRO, was dated Dec 9, 2025. Across all open-market trades the lifetime net is −$1.5M, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

1

Total Filings

22

Lifetime Open-Market Net

-$1.46M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Akero Therapeutics, Inc. (AKRO) Delisted See Remarks 0 $54.65 $0 -$1.46M 17 2025-12-09

Recent Filings

22 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2025-12-09 Akero Therapeutics, Inc. (AKRO) Delisted Disp (D) −29,891 $0 EDGAR
2025-07-03 Akero Therapeutics, Inc. (AKRO) Delisted Sell (S) −2,000 -$105.8K EDGAR
2025-07-02 Akero Therapeutics, Inc. (AKRO) Delisted Grant (A) +193 $4.6K EDGAR
2025-07-01 Akero Therapeutics, Inc. (AKRO) Delisted Notice (144) −2,000 -$106.7K EDGAR
2025-06-20 Akero Therapeutics, Inc. (AKRO) Delisted Sell (S) −875 -$47.8K EDGAR
2025-06-20 Akero Therapeutics, Inc. (AKRO) Delisted Mixed — -$68.5K EDGAR
2025-06-12 Akero Therapeutics, Inc. (AKRO) Delisted Sell (S) −919 -$49.6K EDGAR
2025-06-04 Akero Therapeutics, Inc. (AKRO) Delisted Mixed — -$121.8K EDGAR
2025-05-23 Akero Therapeutics, Inc. (AKRO) Delisted Mixed — -$22.5K EDGAR
2025-05-22 Akero Therapeutics, Inc. (AKRO) Delisted Notice (144) −10,000 -$483.5K EDGAR
Showing 1–10 of 22
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.